• ACE2, an enzyme that physiologically counters RAAS activation, is the functional receptor to SARS-CoV-2, the virus responsible for the Covid-19 pandemic • Select preclinical…
Paper describing experiments showing ARB reduced SARS-CoV-induced disease in mouse model. Trial of ARBs for SARS-CoV-2 (COVID19) registered NCT04312009
NEJM Jwatch with references: Although offering a promising therapeutic and vaccine target against SARS-CoV-2, these new findings remind us that the viral pathogenesis of COVID-19…
Table collating recommendations from the various countries societies on use of ACEi/ ARB – all essentially recommend continuation
There has been an unprecedented interest in this topic. Hence we have added more details and moved this section from the main page to a…
We suggest that patients with cardiac diseases, hypertension, or diabetes, who are treated with ACE2-increasing drugs, are at higher risk for severe COVID-19 infection and,…